| DC41847 |
AMY-101 acetate |
AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation. |
|
| DC41858 |
FSL-1 TFA |
FSL-1 TFA, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection. FSL-1 TFA induces MMP-9 production through TLR2 and NF-κB/AP-1 signaling pathways in monocytic THP-1 cells. |
|
| DC41982 |
Human PD-L1 inhibitor II |
Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity. |
|
| DC41988 |
Human PD-L1 inhibitor IV |
Human PD-L1 inhibitor IV, a polypeptide, is a competitive human PD-1 protein inhibitor with a Kd value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1. |
|
| DC41989 |
Human PD-L1 inhibitor V |
Human PD-L1 inhibitor V, a polypeptide, is a competitive human PD-1 protein inhibitor with a Kd value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1. |
|
| DC42066 |
Human PD-L1 inhibitor III |
Human PD-L1 inhibitor III is a human PD-L1 inhibitor. |
|
| DC42101 |
Phenethyl ferulate |
Phenethyl ferulate is a major constituent ofQianghuo, shows inhibitory activity against cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) with IC50 values of 4.35 μM and 5.75 μM, respectively. |
|
| DC42110 |
Phenidone |
Phenidone, an orally active dual inhibitor of cyclooxygenase (COX) and lipoxygenase (LOX), ameliorates rat paralysis in experimental autoimmune encephalomyelitis. Phenidone is a potent hypotensive agent in the spontaneously hypertensive rat. Phenidone is used as a photographic developer. |
|
| DC42130 |
Pelargonidin chloride |
Pelargonidin chloride is a scavenger of nitric oxide radical and has antioxidant activities. |
|
| DC42322 |
HS271 |
HS271 is a highly potent, orally active and selective IRAK4, with an IC50 of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic properties. |
|
| DC42323 |
Tetrahydroxyquinone hydrate |
Tetrahydroxyquinone hydrate (Tetrahydroxy-1,4-benzoquinone hydrate), a primitive anticataract agent, is a redox active benzoquinone. Tetrahydroxyquinone hydrate can take part in a redox cycle with semiquinone radicals, leading to the formation of reactive oxygen species (ROS). |
|
| DC42461 |
Veledimex (S enantiomer) |
Veledimex S enantiomer (INXN-1001 S enantiomer) is the S enantiomer of veledimex. Veledimex is an oral activator ligand for a proprietary gene therapy promoter system, and a moderate of and substrate for CYP3A4/5. |
|
| DC42505 |
IRAK-4 protein kinase inhibitor 2 |
IRAK-4 protein kinase inhibitor 2 (compound 1) is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4), with an IC50 of 4 μM. IRAK-4 protein kinase inhibitor 2 can be used for the research of inflammatory and immune-related conditions or disorders. |
|
| DC42506 |
S-Methylisothiourea sulfate |
S-Methylisothiourea sulfate is a potent, selective and competitive inhibitor of inducible nitric oxide synthase (iNOS). S-Methylisothiourea sulfate exerts beneficial effects in rodent models of septic shock. |
|
| DC42714 |
BMS-8
Featured
|
BMS-8 inhibits the PD-1/PD-L1 interaction with IC50 of 7.2 μM. BMS-8, binds directly to PD-L1 and induces formation of PD-L1 homodimers, which in turn prevents the interaction with PD-1[1]. |
|
| DC43963 |
FD-IN-1 |
FD-IN-1 (Compound 12) is an orally bioavailable and selective factor D (FD) inhibitor with an IC50 of 12 nM. Complement FD, a highly specific S1 serine protease, plays a central role in the alternative complement pathway of the innate immune system. FD-IN |
|
| DC43964 |
Gallic acid hydrate |
Gallic acid (3,4,5-Trihydroxybenzoic acid) hydrate is a natural polyhydroxyphenolic compound and an free radical scavenger to inhibit cyclooxygenase-2 (COX-2). Gallic acid hydrate has various activities, such as antimicrobial, antioxidant, antimicrobial, |
|
| DC44001 |
SK1-I hydrochloride |
SK1-I hydrochloride (BML-258 hydrochloride), an analog of sphingosine, is an isozyme-specific competitive SPHK1 inhibitor with a Ki value of 10 µM. SK1-I hydrochloride (BML-258 hydrochloride) has good water solubility. SK1-I hydrochloride (BML-258 hydroch |
|
| DC44002 |
SK1-I |
SK1-I (BML-258), an analog of sphingosine, is an isozyme-specific competitive SPHK1 inhibitor with a Ki value of 10 µM. SK1-I (BML-258) has good water solubility. SK1-I (BML-258) shows no activity at SPHK1 PKCα, PKCδ, PKA, AKT1, ERK1, EGFR, CDK2, IKKβ or |
|
| DC44151 |
Complement factor D-IN-2
Featured
|
Complement factor D-IN-2 is an inhibitor of complement factor D extracted from patent WO2015130838A1, compound 190. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases. |
|
| DC44152 |
Emlenoflast sodium (MCC7840 sodium)
Featured
|
MCC7840 sodium, a sulfonylurea, is a potent and selective inhibitor of NLRP3 inflammasome, with an IC50 of <100 nM. MCC7840 sodium can be used for the research of inflammatory diseases. |
|
| DC44153 |
MCC7840
Featured
|
MCC7840, a sulfonylurea, is a potent and selective inhibitor of NLRP3 inflammasome, with an IC50 of <100 nM. MCC7840 can be used for the research of inflammatory diseases. |
|
| DC44154 |
PD-1/PD-L1-IN 3
Featured
|
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases. |
|
| DC44155 |
TPP-1 |
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function. |
|
| DC44156 |
TPP-1 TFA |
TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (KD=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function. |
|
| DC44157 |
PD-1/PD-L1-IN-NP19
Featured
|
PD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effects. |
|
| DC44158 |
IACS-8803 disodium |
IACS-8803 disodium is a highly potent cyclic dinucleotide STING agonist. IACS-8803 disodium has a robust systemic antitumor efficacy. |
|
| DC44508 |
MEG hemisulfate |
MEG (Mercaptoethylguanidine) hemisulfate is a potent and selective inhibitor of the inducible NO synthase (iNOS), with EC50s of 11.5, 110, and 60 μM for iNOS, ecNOS, and bNOS respectively in tissue homogenates. MEG hemisulfate is also a potent scavenger of peroxynitrite and inhibits peroxynitrite-induced oxidative processes. MEG hemisulfate has a protective effect in many experimental models of inflammation, including ischemia/reperfusion injury, periodontitis, hemorrhagic shock, inflammatory bowel disease, and endotoxic and septic shock. |
|
| DC44556 |
PMX 205 |
PMX 205 is a potent complement C5a receptor (C5aR; CD88) antagonist. |
|
| DC44557 |
Teriflunomide impurity 3 |
Teriflunomide impurity 3 (4-Amino-N-(4-trifluoromethylphenyl)benzamide) is a selective COX-1 inhibitor with an IC50 of 30 µM. Teriflunomide impurity 3 is less active against COX-2 (IC50>100 µM). |
|
